NASDAQ:ANIPANI Pharmaceuticals Stock Price, Forecast & News

ANI Pharmaceuticals' stock was trading at $38.30 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ANIP shares have decreased by 18.2% and is now trading at $31.34. View which stocks have been most impacted by Coronavirus.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ANI Pharmaceuticals in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for ANI Pharmaceuticals.

ANI Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for ANI Pharmaceuticals.

ANI Pharmaceuticals Inc (NASDAQ:ANIP) released its quarterly earnings results on Thursday, May, 7th. The specialty pharmaceutical company reported $1.04 earnings per share for the quarter, topping analysts' consensus estimates of $0.89 by $0.15. The specialty pharmaceutical company had revenue of $49.77 million for the quarter, compared to the consensus estimate of $49.40 million. ANI Pharmaceuticals had a positive return on equity of 23.92% and a negative net margin of 0.67%. View ANI Pharmaceuticals' earnings history.

3 brokers have issued 12-month target prices for ANI Pharmaceuticals' stock. Their forecasts range from $40.00 to $58.00. On average, they anticipate ANI Pharmaceuticals' share price to reach $49.00 in the next year. This suggests a possible upside of 56.3% from the stock's current price. View analysts' price targets for ANI Pharmaceuticals.

Media stories about ANIP stock have trended negative recently, InfoTrie reports. The research group scores the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. ANI Pharmaceuticals earned a news sentiment score of -2.1 on InfoTrie's scale. They also gave press coverage about the specialty pharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the next several days. View the latest news about ANI Pharmaceuticals.

ANI Pharmaceuticals saw a decline in short interest during the month of June. As of June 30th, there was short interest totaling 559,500 shares, a decline of 10.1% from the June 15th total of 622,200 shares. Based on an average trading volume of 128,300 shares, the short-interest ratio is presently 4.4 days. Approximately 5.8% of the shares of the company are short sold. View ANI Pharmaceuticals' Current Options Chain.

Some companies that are related to ANI Pharmaceuticals include Mersana Therapeutics (MRSN), ZEALAND PHARMA/S (ZEAL), Revance Therapeutics (RVNC), Karyopharm Therapeutics (KPTI), Akcea Therapeutics (AKCA), MacroGenics (MGNX), Portola Pharmaceuticals (PTLA), Kiniksa Pharmaceuticals (KNSA), Esperion Therapeutics (ESPR), Innoviva (INVA), Heron Therapeutics (HRTX), Amneal Pharmaceuticals (AMRX), Arvinas (ARVN), Tricida (TCDA) and Theravance Biopharma (TBPH). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other ANI Pharmaceuticals investors own include Abraxas Petroleum (AXAS), Gilead Sciences (GILD), Micron Technology (MU), Alibaba Group (BABA), Teva Pharmaceutical Industries (TEVA), Broadcom (AVGO), AbbVie (ABBV), Cisco Systems (CSCO), Intel (INTC) and NXP Semiconductors (NXPI).

ANI Pharmaceuticals trades on the NASDAQ under the ticker symbol "ANIP."

Shares of ANIP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ANIP stock can currently be purchased for approximately $31.34.

ANI Pharmaceuticals has a market capitalization of $379.40 million and generates $206.55 million in revenue each year. The specialty pharmaceutical company earns $6.09 million in net income (profit) each year or $4.46 on an earnings per share basis. ANI Pharmaceuticals employs 299 workers across the globe.

The official website for ANI Pharmaceuticals is www.anipharmaceuticals.com.

ANI Pharmaceuticals' mailing address is 210 Main Street West, Baudette MN, 56623. The specialty pharmaceutical company can be reached via phone at 218-634-3500 or via email at [email protected]